Leukemia research has revolutionized treatment with CAR-T cell therapy, targeted therapies, and improved stem cell transplantation techniques.
PATHFINDER 2, a prospective, interventional cohort study of 35,878 adults aged 50 and older with no clinical suspicion of cancer, evaluated the performance and safety of a blood-based multi-cancer early detection (MCED) test that analyzes cell-free DNA methylation patterns to detect a shared cancer signal and predict its tissue of origin.
A phase 2, open-label, nonrandomized trial across five Chinese pediatric centers tested a bicistronic CD19/CD22 CAR T-cell product designed to reduce antigen-loss relapse after CD19-only CAR-T therapy in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia.
A registry-based analysis of 11,681 US interventional cancer trials registered on ClinicalTrials.gov between 2008 and 2024 found that industry sponsors now outnumber federal sponsors nearly 5 to 1 (4.53-to-1 overall), with the ratio widening from 2.72-to-1 in 2008–2012 to 6.44-to-1 in 2019–2024.
Phase 3 randomized trial of 909 patients with previously untreated CLL across 174 sites in 13 countries